The Impact of Hospitalization on Ambulatory Blood Pressure and Intraocular Pressure

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-03-31

Study Completion Date

2009-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the effect of hospital admission on 24-hour ambulatory blood pressure (ABP) in hypertensive subjects.Treated or untreated hypertensive adults with open angle glaucoma underwent in-hospital and outpatient 24-hour ABP monitoring, in random order 4 weeks apart.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Blood Pressure

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Hypertension Ambulatory measurement

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CROSSOVER

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age \>30 years old.
* subject has signed an informed consent.
* patient has untreated ocular hypertension (IOP at 10:00 between 22-34 mm Hg)
* patient has stage 1 arterial hypertension with or without therapy

Exclusion Criteria

* secondary hypertension.
* stage 2 or 3 hypertension, history of renal disease.
* sleep apnea.
* diabetes mellitus
* acute or chronic inflammation.
* myocardial infarction or unstable angina within the past 6 months.
* heart failure NYHA class III-IV.
* active liver disease.
* pregnancy.
* history of drug or alcohol abuse, or any other condition with poor prognosis.
* treatment with non-steroid anti-inflammatory agents, corticosteroids, beta-blockers, or any other regimen that could affect BP levels.
* smoking

Minimum Eligible Age

30 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

1st Department of Internal Medicine, Aristotle University, Thessaloniki

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

A3244

Identifier Type: -

Identifier Source: org_study_id